Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to $39000.0.

  • Mereo BioPharma's Depreciation & Amortization (CF) fell 6100.0% to $39000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $159000.0, marking a year-over-year decrease of 4903.85%. This contributed to the annual value of $143000.0 for FY2024, which is 2850.0% down from last year.
  • Latest data reveals that Mereo BioPharma reported Depreciation & Amortization (CF) of $39000.0 as of Q3 2025, which was down 6100.0% from $44000.0 recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's Depreciation & Amortization (CF) ranged from a high of $100000.0 in Q2 2023 and a low of $38000.0 during Q4 2024
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $44000.0 (2025), whereas its average is $64818.2.
  • As far as peak fluctuations go, Mereo BioPharma's Depreciation & Amortization (CF) changed by 0.0% in 2024, and later plummeted by 6100.0% in 2025.
  • Quarter analysis of 3 years shows Mereo BioPharma's Depreciation & Amortization (CF) stood at $71000.0 in 2023, then plummeted by 46.48% to $38000.0 in 2024, then grew by 2.63% to $39000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $39000.0 in Q3 2025, compared to $44000.0 in Q2 2025 and $38000.0 in Q1 2025.